Rapid weight loss takes lean mass along with fat. What DXA trials show, exact daily protein targets, and the resistance training protocol to keep muscle.
25–40%Lean mass share of total weight lost in unmanaged caloric deficits
1.2–1.6gDaily protein per kg body weight recommended to preserve muscle
39%STEP-1 DXA substudy lean mass proportion of total weight lost
2–3×Weekly resistance training sessions needed to signal retention
Key takeaways
Rapid weight loss from GLP-1 medications typically consists of 60–75% fat mass and 25–40% lean body mass if diet and resistance training are not managed.
In the STEP-1 DXA sub-study on semaglutide, lean mass accounted for approximately 39% of total weight lost — a ratio consistent with rapid caloric restriction.
Preserving skeletal muscle requires two primary stimuli: progressive resistance training (at least 2–3 sessions per week) and adequate daily protein (1.2 to 1.6 grams per kilogram of body weight).
Severe hypocaloric deficits (<1,000–1,200 kcal/day) triggered by excessive appetite suppression accelerate sarcopenic lean tissue breakdown.
When you lose weight rapidly on semaglutide (Wegovy, Ozempic) or tirzepatide (Mounjaro, Zepbound), the scale measures total mass lost — not purely adipose tissue. Body composition sub-studies using dual-energy X-ray absorptiometry (DXA) scans provide the clearest clinical picture:
STEP-1 Trial (Semaglutide 2.4 mg): In the DXA sub-study of 140 participants, average weight loss was 15.3 kg. Of that, 8.4 kg was fat mass and 5.3 kg was lean body mass (~39% of total weight lost). However, the ratio of lean mass to total body mass improved from 63% to 68% because fat mass dropped more drastically.
SURMOUNT-1 Trial (Tirzepatide 15 mg): Participants in the body composition substudy lost ~25.8% fat mass and 10.9% lean mass (~29% of total reduction as lean mass), resulting in a net improvement in body composition proportion.
Why appetite suppression risks lean tissue
GLP-1 receptor agonists delay gastric emptying and act on hypothalamic satiety centres. When food noise vanishes, many patients unintentionally consume under 1,000 calories per day with very low protein intake. In a steep energy deficit without mechanical muscle tension, the liver converts amino acids from skeletal muscle into glucose via gluconeogenesis.
Protein targets and practical intake
Clinical nutrition guidelines for weight-reduced individuals recommend consuming 1.2 to 1.6 grams of protein per kilogram of body weight daily (or ~0.6 to 0.8 grams per pound of target weight).
Protein distribution: Aim for 25–35 grams of high-quality protein per meal to trigger muscle protein synthesis (MPS).
Liquid supplementation: When early satiety makes dense whole foods difficult, whey isolate or clear plant protein shakes help hit targets without feeling uncomfortably full.
Aerobic cardio burns calories, but only mechanical tension from resistance training signals muscle retention during severe caloric deficits. Aim for 2 to 3 sessions weekly targeting major muscle groups (squats, deadlifts, presses, rows) with progressive overload.
How to monitor body composition
Do not rely purely on bathroom scales. Track waist-to-hip ratio, gym strength metrics (if lifting numbers collapse, you are losing muscle), and periodic DEXA or multi-frequency InBody scans every 3 to 6 months.
Common questions
Does Ozempic cause more muscle loss than other diets?
No. Clinical trials show the proportion of lean mass lost (25–40%) is virtually identical to other rapid weight-loss interventions, including bariatric surgery and severe caloric restriction.
Should I take creatine while on Wegovy or Zepbound?
Creatine monohydrate (3–5g daily) supports intracellular hydration and muscular strength without interacting with GLP-1 receptor pharmacology.
What happens to my metabolism if I lose muscle?
Skeletal muscle accounts for a significant portion of basal metabolic rate (BMR). Preserving muscle prevents severe metabolic slowdown, making long-term weight maintenance significantly easier.
Sources
Every figure on this page traces to one of these. Regulatory documents and
peer-reviewed primary research only — see our editorial policy
for what we accept as a source.
Wilding JPH et al. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study. Journal of the Endocrine Society, 2021. View source
Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1 body composition sub-study). NEJM, 2022. View source
Jäger R et al. International Society of Sports Nutrition Position Stand: protein and exercise. J Int Soc Sports Nutr, 2017. View source
WEGOVY (semaglutide) injection, US prescribing information. FDA, 2025. View source
Track your protein and dose schedule
GLPme helps you track your weekly injections, symptom trends, and body metrics in one private timeline.